Unlock instant, AI-driven research and patent intelligence for your innovation.

Combination treatment of glaucoma

A technology of glaucoma and eye drops, applied in the field of combined therapy of glaucoma, can solve problems such as drug delivery and compliance problems

Inactive Publication Date: 2011-06-22
QLT INC
View PDF13 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, dosing and compliance are often problematic

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination treatment of glaucoma
  • Combination treatment of glaucoma
  • Combination treatment of glaucoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0179] Implants: The Punctal Plug Drug Delivery System (PPDS) may consist of a drug insert configured to be placed into a suitable commercially available punctal plug with a pre-existing bore. All materials used in the construction of the drug insert are medical grade materials that have passed a series of safety / toxicity tests. The drug insert is a thin-walled polyimide tube filled with latanoprost dispersed in Nusil 6385 (cured medical grade solid silicone). Cured silicone was used as a solid non-erosive matrix from which latanoprost was slowly eluted. The distal end of the drug insert was sealed with a cured film of solid Loctite 4305 medical grade adhesive (cyanoacrylate). The polyimide sleeve is inert and, together with the adhesive, provides structural support and barrier to drug diffusion on both sides and through the distal end of the drug insert. The drug insert is seated in the lumen of the punctal plug and held in place by an interference fit. The assembled syste...

Embodiment 2

[0187] The lacrimal plug delivery system implant and eye drop auxiliary composition are the same as in Example 1. The eye drop adjunct composition was administered once or twice daily for 2 weeks, followed by insertion of the punctal plug delivery system, with no washout period between the 2 week administration of the eye drop adjunct composition and implant insertion. The implant remains inserted in the puncta for up to 12 weeks. Intraocular pressure was monitored as in Example 1.

Embodiment 3

[0189] The lacrimal plug delivery system implant and eye drop auxiliary composition are the same as in Example 1. From the day of insertion of the punctum plug delivery system, the eye drop adjuvant composition was administered once or twice a day for 5 days. The punctal plug delivery system remains in the punctum for up to 12 weeks. Intraocular pressure was monitored as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The methods described herein provide reduction of intraocular pressure by administering a sustained release formulation including latanoprost and a pharmaceutically acceptable vehicle and administering an eye drop adjunctive composition to the eye of a patient. The sustained release formulation can release latanoprost continuously for at least 90 days from a punctum plug delivery system. The eye drop adjunctive composition can also include latanoprost.

Description

[0001] priority statement [0002] The benefit of priority of U.S. Provisional Patent Application Serial No. 61 / 075,284, filed June 24, 2008, entitled "Combination Treatment of Glaucoma," the specification of which is hereby incorporated by reference in its entirety, is hereby claimed. Background technique [0003] Glaucoma is a collection of disorders characterized by progressive visual field loss due to optic nerve damage. It is the leading cause of blindness in the United States, affecting 1-2% of individuals aged 60 and over. Despite the presence of many risk factors (age, race, myopia, family history, and injury) associated with the development of glaucoma, elevated intraocular pressure (also called ocular hypertension) is successfully managed and associated with glaucomatous optic neuropathy. Mitigate the only associated risk factor. Public health figures (figure) estimate that 2.5 million Americans exhibit ocular hypertension. [0004] To control glaucoma and ocular ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61F2/00A61F13/00
CPCA61K9/0048A61K9/0051A61K31/5575A61P27/02A61P27/06
Inventor Z·巴特纳
Owner QLT INC